Glaucoma News

SAN FRANCISCO — At the Glaucoma 360: New Horizons Forum, Casey C. Kopczynski, PhD, chief scientific officer and co-founder of Aerie Pharmaceuticals, explains the company’s plan to test its AR-13503 sustained-release Rho kinase inhibitor implant for the treatment of glaucoma.

SAN FRANCISCO — NCX 470, Nicox’s novel second-generation nitric oxide-donating bimatoprost analog, showed superior IOP lowering compared with latanoprost in a phase 2 clinical trial, according to a speaker here.

SAN FRANCISCO — At the Glaucoma 360: New Horizons Forum, Daria Lemann-Blumenthal, LLB, EMBA, CEO of Belkin Laser, discusses the company’s clinical-stage automated 1-second laser treatment.

SAN FRANCISCO — An intracameral travoprost implant reduced IOP for up to 9 months in preliminary results from a phase 1 study, according to a speaker here.

KOLOA, Hawaii — At Hawaiian Eye 2020, Christine L. Larsen, MD, discusses her presentation on the role of medical therapy as primary treatment of glaucoma and ocular hypertension vs. selective laser trabeculoplasty as first-line treatment.

SAN FRANCISCO — The iDose, a titanium implant from Glaukos for continuous drug delivery, has shown positive phase 2 results and is currently in a phase 3 program, according to a speaker here.

KOLOA, Hawaii — At Hawaiian Eye 2020, Tom Mitro, president and chief operating officer of Aerie Pharmaceuticals, discusses recent data, including results from the MOST phase 4 trial focusing on the use of Rhopressa (netarsudil ophthalmic solution 0.02%) in real-world experiences.

KOLOA, Hawaii — At Hawaiian Eye 2020, Steven D. Vold, MD, discusses the use of Vyzulta (latanoprostene bunod ophthalmic solution 0.024%, Bausch + Lomb) in treating glaucoma diagnoses. “It definitely has a place in your glaucoma treatment paradigm,” Vold said.

It’s not unusual for us to have more than three dozen patients on our schedules the morning after a typical cataract surgery day. Because the vast majority are doing well 1 day postop, these are usually brief examinations.

The progression rate of normal tension glaucoma with myopia may be slow even without the uses of glaucoma medications, according to findings published in the American Journal of Ophthalmology.